LAVA Therapeutics (LVTX) Competitors $1.03 +0.04 (+4.16%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends LVTX vs. ANRO, IMUX, SKYE, MNOV, CNTX, AVTX, TNXP, PYXS, IPSC, and SCLXShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Alto Neuroscience (ANRO), Immunic (IMUX), Skye Bioscience (SKYE), MediciNova (MNOV), Context Therapeutics (CNTX), Avalo Therapeutics (AVTX), Tonix Pharmaceuticals (TNXP), Pyxis Oncology (PYXS), Century Therapeutics (IPSC), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Alto Neuroscience Immunic Skye Bioscience MediciNova Context Therapeutics Avalo Therapeutics Tonix Pharmaceuticals Pyxis Oncology Century Therapeutics Scilex LAVA Therapeutics (NASDAQ:LVTX) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability. Which has better valuation & earnings, LVTX or ANRO? Alto Neuroscience has lower revenue, but higher earnings than LAVA Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLAVA Therapeutics$7.35M3.55-$41.97M-$1.03-1.00Alto Neuroscience$210K499.59-$36.31MN/AN/A Do analysts prefer LVTX or ANRO? LAVA Therapeutics currently has a consensus price target of $3.33, indicating a potential upside of 223.62%. Alto Neuroscience has a consensus price target of $20.00, indicating a potential upside of 414.14%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LAVA Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.63 Does the media prefer LVTX or ANRO? In the previous week, LAVA Therapeutics had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for LAVA Therapeutics and 5 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.28 beat LAVA Therapeutics' score of 0.24 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LAVA Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LVTX or ANRO more profitable? Alto Neuroscience has a net margin of 0.00% compared to LAVA Therapeutics' net margin of -228.02%. Alto Neuroscience's return on equity of -49.28% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LAVA Therapeutics-228.02% -62.22% -29.37% Alto Neuroscience N/A -49.28%-33.52% Does the MarketBeat Community favor LVTX or ANRO? LAVA Therapeutics received 11 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 82.35% of users gave Alto Neuroscience an outperform vote while only 69.44% of users gave LAVA Therapeutics an outperform vote. CompanyUnderperformOutperformLAVA TherapeuticsOutperform Votes2569.44% Underperform Votes1130.56% Alto NeuroscienceOutperform Votes1482.35% Underperform Votes317.65% SummaryAlto Neuroscience beats LAVA Therapeutics on 9 of the 13 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.11M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-1.0010.5990.0517.18Price / Sales3.55195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book0.305.094.784.78Net Income-$41.97M$151.83M$120.31M$225.60M7 Day Performance-7.21%-2.13%-1.92%-1.23%1 Month Performance-30.41%-3.10%11.50%3.36%1 Year Performance-31.79%11.54%30.59%16.60% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics3.0636 of 5 stars$1.03+4.2%$3.33+223.6%-31.3%$26.11M$7.35M-1.0060Analyst ForecastGap DownANROAlto Neuroscience3.2643 of 5 stars$3.83flat$20.00+422.2%N/A$103.30M$210,000.000.00N/AGap UpIMUXImmunic2.933 of 5 stars$1.15+1.3%$11.80+930.6%-20.6%$103.14MN/A-0.9270Positive NewsSKYESkye Bioscience2.1878 of 5 stars$3.38+0.9%$18.67+452.3%-10.6%$102.54MN/A0.0011News CoveragePositive NewsGap DownMNOVMediciNova2.1642 of 5 stars$2.09-0.5%$9.00+330.6%+43.7%$102.51M$1M-9.9510Analyst ForecastPositive NewsCNTXContext Therapeutics2.9747 of 5 stars$1.36-2.5%$6.80+401.8%+1.0%$101.62MN/A-1.477Positive NewsGap DownAVTXAvalo Therapeutics3.7075 of 5 stars$9.73+5.4%N/A-13.7%$101.13M$820,000.000.0040Analyst ForecastNews CoveragePositive NewsTNXPTonix Pharmaceuticals3.6158 of 5 stars$0.53+122.0%$53.50+9,920.6%-95.0%$99.78M$11.29M0.00103High Trading VolumePYXSPyxis Oncology2.1397 of 5 stars$1.68+3.4%$10.00+497.0%-2.9%$99.61MN/A-1.5760Analyst ForecastNews CoveragePositive NewsIPSCCentury Therapeutics1.8159 of 5 stars$1.16-5.3%$11.60+904.3%-52.6%$98.21M$2.68M-0.66170Gap DownHigh Trading VolumeSCLXScilex3.1746 of 5 stars$0.51+0.2%$11.33+2,128.8%-65.6%$97.53M$46.74M-0.3580 Related Companies and Tools Related Companies Alto Neuroscience Alternatives Immunic Alternatives Skye Bioscience Alternatives MediciNova Alternatives Context Therapeutics Alternatives Avalo Therapeutics Alternatives Tonix Pharmaceuticals Alternatives Pyxis Oncology Alternatives Century Therapeutics Alternatives Scilex Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LVTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LVTX Stock Alerts